Revolution Health buys two online companies in battle to unseat WebMD

Share this article:
Revolution Health CEO Steve Case
Revolution Health CEO Steve Case

Revolution Health has acquired the online properties HealthTalk and SparkPeople in an attempt to dethrone WebMD as the Web's No.1 health destination. Financial terms of the deals were not disclosed.

Seattle-based HealthTalk serves as an online health information network for patients and caregivers living with a chronic condition. SparkPeople, based in Cincinnati, is designed to help consumers set diet and fitness goals.

“With HealthTalk and SparkPeople,” Revolution Health Group CEO Steve Case said in a statement. “Revolution Health Network is now the second largest health property on the Internet, generating more page views than MayoClinic, EverydayHealth, Yahoo! Health, iVillage Total Health and RealAge combined, putting us in striking distance of being number one.”

Following the acquisition, Revolution Health Network now owns or co-owns five Web sites including, and

In late October, Revolution Health laid off 60 employees in an effort to cut costs to match lower-than-expected revenue. At the time, the company said it expected to have 180 employees by Jan. 1. However, with the HealthTalk acquisition, Washington, DC-based Revolution Health will add at least 50 more workers, although those employees are expected to remain to in Seattle.

WebMD Health led the top five Web sites in the online health category with 19.9 million unique visitors (UVs) for the month of October, according to the latest statistics available from ComScore Media Metrix.

WebMD Health was trailed by EverydayHealth with 12 million UVs, NIH.GOV with 9.6 million UVs, Revolution Health Network with nearly 8 million UVs and Health with 7.7 million UVs.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.